Anzeige
Mehr »
Dienstag, 02.06.2026 - Börsentäglich über 12.000 News
Entsteht hier die nächste Quantum-Story?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41EP1 | ISIN: US92943X1046 | Ticker-Symbol: H1O
NASDAQ
02.06.26 | 16:40
2,320 US-Dollar
-0,85 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VYOME HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
VYOME HOLDINGS INC 5-Tage-Chart

Aktuelle News zur VYOME Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrVyome Holdings, Inc. reports Q1 results1
FrVyome Holdings, Inc - 8-K, Current Report1
22.04.Vyome: Positive Phase-2-Daten für Wundbehandlung bei Krebspatienten1
22.04.Vyome reports positive phase 2 results for cancer wound treatment2
06.04.Vyome to present VT-1953 Phase 2 data at cancer research meeting1
26.03.Vyome Holdings, Inc. reports FY results1
VYOME Aktie jetzt für 0€ handeln
18.03.Vyome Holdings, Inc - 10-K, Annual Report-
02.02.Vyome sichert sich 5,29 Mio. US-Dollar zur Finanzierung der Phase-3-Studie für MFW-Behandlung4
02.02.Vyome raises $5.29 million to fund phase 3 trial of MFW treatment2
28.01.Vyome Holdings, Inc - 8-K, Current Report1
27.01.Vyome-Aktie springt nach Milliarden-Bewertung für Medikamentenkandidaten4
23.12.25Vyome Holdings, Inc - 8-K, Current Report-
08.12.25Vyome-Aktie steigt nach positiven Studienergebnissen zur Behandlung von Wundgeruch2
17.09.25Morning Market Movers: SciSparc, Vyome Holdings, Presidio Property Trust, FG Nexus See Big Swings679BEIJING (dpa-AFX) - At 7:55 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
13.08.25Vyome Therapeutics Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND737Effective as of Commencement of Trading on August 15, 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare...
► Artikel lesen
07.08.25ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics290Expected to be Effective as of Commencement of Trading on August 15, 2025 IRVINE, Calif.--(BUSINESS WIRE)--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved...
► Artikel lesen
01.07.25ReShape Lifesciences Inc: ReShape Lifesciences Granted U.S. Patent Related to an Intragastric Balloon System290IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8...
► Artikel lesen
27.06.25ReShape Lifesciences Inc: ReShape Lifesciences Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement496IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June...
► Artikel lesen
26.06.25ReShape Lifesciences Inc: ReShape Lifesciences Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys324Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26,...
► Artikel lesen
12.06.25ReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets1.023IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1